-
Je něco špatně v tomto záznamu ?
Aristolochic acid and its effect on different cancers in uro-oncology
K. Rebhan, IE. Ertl, SF. Shariat, AP. Grollman, T. Rosenquist,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- adukty DNA genetika metabolismus MeSH
- balkánská nefropatie chemicky indukované MeSH
- karcinogeny MeSH
- kyseliny aristolochové toxicita MeSH
- léky rostlinné čínské škodlivé účinky MeSH
- lidé MeSH
- nádory močového měchýře chemicky indukované MeSH
- urologické nádory chemicky indukované MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE OF REVIEW: To acquaint urologists with aristolochic acid nephropathy, an iatrogenic disease that poses a distinct threat to global public health. In China alone, 100 million people may currently be at risk. We illustrate the power of molecular epidemiology in establishing the cause of this disease. RECENT FINDINGS: Molecular epidemiologic approaches and novel mechanistic information established a causative linkage between exposure to aristolochic acid and urothelial carcinomas of the bladder and upper urinary tract. Noninvasive tests are available that detect urothelial cancers through the genetic analysis of urinary DNA. Combined with cytology, some of these tests can detect 95% of patients at risk of developing bladder and/or upper urothelial tract cancer. Robust biomarkers, including DNA-adduct and mutational signature analysis, unequivocally identify aristolochic acid-induced tumours. The high mutational load associated with aristolochic acid-induced tumours renders them candidates for immune-checkpoint therapy. SUMMARY: Guided by recent developments that facilitate early detection of urothelial cancers, the morbidity and mortality associated with aristolochic acid-induced bladder and upper tract urothelial carcinomas may be substantially reduced. The molecular epidemiology tools that define aristolochic acid-induced tumours may be applicable to other studies assessing potential environmental carcinogens.
Department of Pharmacological Sciences
Department of Urology Comprehensive Cancer Center Medical University of Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027876
- 003
- CZ-PrNML
- 005
- 20210114152532.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOU.0000000000000806 $2 doi
- 035 __
- $a (PubMed)32701724
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rebhan, Katharina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
- 245 10
- $a Aristolochic acid and its effect on different cancers in uro-oncology / $c K. Rebhan, IE. Ertl, SF. Shariat, AP. Grollman, T. Rosenquist,
- 520 9_
- $a PURPOSE OF REVIEW: To acquaint urologists with aristolochic acid nephropathy, an iatrogenic disease that poses a distinct threat to global public health. In China alone, 100 million people may currently be at risk. We illustrate the power of molecular epidemiology in establishing the cause of this disease. RECENT FINDINGS: Molecular epidemiologic approaches and novel mechanistic information established a causative linkage between exposure to aristolochic acid and urothelial carcinomas of the bladder and upper urinary tract. Noninvasive tests are available that detect urothelial cancers through the genetic analysis of urinary DNA. Combined with cytology, some of these tests can detect 95% of patients at risk of developing bladder and/or upper urothelial tract cancer. Robust biomarkers, including DNA-adduct and mutational signature analysis, unequivocally identify aristolochic acid-induced tumours. The high mutational load associated with aristolochic acid-induced tumours renders them candidates for immune-checkpoint therapy. SUMMARY: Guided by recent developments that facilitate early detection of urothelial cancers, the morbidity and mortality associated with aristolochic acid-induced bladder and upper tract urothelial carcinomas may be substantially reduced. The molecular epidemiology tools that define aristolochic acid-induced tumours may be applicable to other studies assessing potential environmental carcinogens.
- 650 _2
- $a kyseliny aristolochové $x toxicita $7 D034341
- 650 _2
- $a balkánská nefropatie $x chemicky indukované $7 D001449
- 650 _2
- $a karcinogeny $7 D002273
- 650 _2
- $a adukty DNA $x genetika $x metabolismus $7 D018736
- 650 _2
- $a léky rostlinné čínské $x škodlivé účinky $7 D004365
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory močového měchýře $x chemicky indukované $7 D001749
- 650 _2
- $a urologické nádory $x chemicky indukované $7 D014571
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ertl, Iris E $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria. Department of Urology, Weill Cornell Medical College, New York, New York. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
- 700 1_
- $a Grollman, Arthur P $u Department of Pharmacological Sciences. Department of Medicine, Stony Brook University, Stony Brook, New York, USA.
- 700 1_
- $a Rosenquist, Thomas $u Department of Pharmacological Sciences.
- 773 0_
- $w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 5 (2020), s. 689-695
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32701724 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152530 $b ABA008
- 999 __
- $a ok $b bmc $g 1608211 $s 1119056
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 30 $c 5 $d 689-695 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
- LZP __
- $a Pubmed-20210105